SGLTR V (Remogliflozin Etabonate (100mg) + Vildagliptin (50mg))

Sgltr-V Tablet is a formulation that combines two active ingredients to assist in managing type 2 diabetes mellitus. It has been authorized for use in individuals aged 18 years and older, aiming to enhance blood sugar regulation. This medication is typically utilized when other diabetes treatments fail to achieve adequate control of blood glucose levels. Sgltr-V Tablet can be administered as a standalone treatment or in conjunction with other diabetic drugs. The effectiveness of all diabetic medications increases when paired with a balanced diet and consistent physical activity. It is advised to take this medication twice a day or as directed by a healthcare professional to optimize blood sugar management in patients. Consistency in timing and adherence to the medication regimen is essential for maximizing its benefits. It is crucial not to discontinue use unless specifically instructed by a healthcare provider. This medication aids in maintaining stable blood sugar levels, thereby potentially reducing the risk of severe complications in the long term. Following a prescribed diet and exercise program is vital while taking this medication, as lifestyle choices significantly influence diabetes control. Potential adverse effects include diarrhea, nausea, vomiting, stomach discomfort, and headaches. Patients also need to be aware of the risk of hypoglycemia, especially if taking other diabetic medications such as insulin or sulfonylureas, and should be educated on recognizing and addressing this condition. Prior to starting this medication, it is important to disclose any history of kidney, liver, heart disease, or pancreatic issues to the healthcare provider. Pregnant or breastfeeding women should seek medical advice before using this treatment. Additionally, it is important to inform the doctor about any other medications being taken to prevent interactions, and caution should be exercised regarding alcohol consumption, as it may lower blood sugar levels. Regular monitoring of kidney function and blood sugar levels will be conducted by the healthcare provider throughout the treatment process.